IMR Press / FBL / Volume 23 / Issue 11 / DOI: 10.2741/4689

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Autoantibodies against muscarinic acetylcholine receptor M3 in Sjogren’s syndrome and corresponding mouse models

Show Less
1 Priority Area Asthma and Allergy, Research Center Borstel, 23845 Borstel, Germany, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL)
2 Xiamen-Borstel Joint Laboratory of Autoimmunity, Medical College of Xiamen University, Xiamen, 361102, China
3 Department of Rheumatology, University of Lubeck, 23538, Lubeck, Germany
Front. Biosci. (Landmark Ed) 2018, 23(11), 2053–2064; https://doi.org/10.2741/4689
Published: 1 June 2018
Abstract

Muscarinic acetylcholine receptor M3 (M3R) is a GPCR on exocrine gland cells involved in fluid secretion. In the last two decades, evidence has been accumulated arguing for a role of autoantibodies (aab) against M3R in the development of Sjögren’s syndrome (SS). In this review, we provide an updated overview on this issue and critically discuss the relation between autoimmunity to M3R and SS pathogenesis. Clinical data as well as findings from experimental disease were summarized in categories addressing the presence of aab against M3R in SS patients, the function of anti-M3R aab, the association of aab against M3R with SS-related phenotypes, in vivo pathogenicity of transferred aab against M3R in mice, and mouse models induced via immunization with M3R. Based on these comprehensive data, we propose a hypothetic model for the role of aab against M3R in the pathogenesis of SS.

Keywords
Muscarinic acetylcholine receptor M3
Autoantibodies
Sjögren’s syndrome
Review
Share
Back to top